Unicycive Therapeutics, Inc.
UNCY
$6.80
$0.8614.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.82M | 3.97M | 3.21M | 2.53M | 2.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.99M | 9.26M | 6.25M | 7.40M | 9.20M |
| Operating Income | -7.99M | -9.26M | -6.25M | -7.40M | -9.20M |
| Income Before Tax | 570.00K | -21.53M | -4.10M | 9.86M | -20.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 570.00K | -21.53M | -4.10M | 9.86M | -20.96M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 570.00K | -21.53M | -4.10M | 9.86M | -20.96M |
| EBIT | -7.99M | -9.26M | -6.25M | -7.40M | -9.20M |
| EBITDA | -7.98M | -9.25M | -6.25M | -7.40M | -9.20M |
| EPS Basic | 0.04 | -2.04 | -0.46 | 0.80 | -6.06 |
| Normalized Basic EPS | 0.03 | -1.27 | -0.29 | 1.62 | -3.75 |
| EPS Diluted | -0.50 | -2.04 | -0.46 | -1.46 | -6.10 |
| Normalized Diluted EPS | 0.03 | -1.27 | -0.29 | 0.65 | -3.75 |
| Average Basic Shares Outstanding | 11.68M | 10.57M | 8.89M | 3.79M | 3.49M |
| Average Diluted Shares Outstanding | 12.38M | 10.57M | 8.89M | 9.41M | 3.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.00% | 11.11% | -- |